Safety, Tolerability and Effectiveness of Generic HAART in HIV-Infected Children in South India
HIV-infected children in resource-limited settings are increasingly gaining greater access to highly active antiretroviral therapy (HAART) but documented longitudinal data remains limited. We aimed to study the clinical and immunological outcomes among 67 South Indian HIV-infected children with >...
Gespeichert in:
| Veröffentlicht in: | Journal of tropical pediatrics (1980) 2009-06, Vol.55 (3), p.155-159 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 159 |
|---|---|
| container_issue | 3 |
| container_start_page | 155 |
| container_title | Journal of tropical pediatrics (1980) |
| container_volume | 55 |
| creator | Kumarasamy, N. Venkatesh, Kartik K. Devaleenol, Bella Poongulali, S. Mothi, S. N. Solomon, Suniti |
| description | HIV-infected children in resource-limited settings are increasingly gaining greater access to highly active antiretroviral therapy (HAART) but documented longitudinal data remains limited. We aimed to study the clinical and immunological outcomes among 67 South Indian HIV-infected children with >18 months of follow-up on HAART at a tertiary HIV care program. The median CD4 cell count at enrolment was 290 cells μl−1 and at treatment initiation was 225 cells μl−1. Patients demonstrated a significant rise in their CD4 cell counts between treatment initiation and after 6 months (701 cells μl−1; p = 0.007), 12 months (741 cells μl−1; p = 0.037), and 18 months of therapy (718 cells μl−1; p = 0.005). The most common adverse events to therapy were nausea (20.9%) and rash (25.4%). Over one-fifth of patients (25.4%) substituted therapy due to toxicities and 19.4% of patients switched to second-line protease inhibitor-containing regimens. In this South Indian pediatric cohort, generic HAART was safe, effective and relatively well tolerated. |
| doi_str_mv | 10.1093/tropej/fmn080 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_224326121</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/tropej/fmn080</oup_id><sourcerecordid>1744954831</sourcerecordid><originalsourceid>FETCH-LOGICAL-c458t-22a2b177ca13d08e880b208feb0e014a5a7ffdc9b56bdbe0b288a5b90eacc1db3</originalsourceid><addsrcrecordid>eNqF0M-L1DAUB_AgijuuHr1KEAQP1s2PNs0ch2HdDq6Iziiyl5AfL2zGTjomrTj_vR1a1qOnF3gf3nv5IvSSkveULPlVn7oj7K_8IRJJHqEFLUVVcCHKx2hBaMkKwbm8QM9y3hNCmCzLp-iCSsmWgssFUlvtoT-9w7uuhaRNaEN_wjo6fO092D78hgg5487jm_GVgsXNavV1h0PEzeZ7sYlnBQ6v70PrEsRzY9sN_T3eRBf0c_TE6zbDi7leom8frnfrprj9fLNZr24LW1ayLxjTzNC6tppyRyRISQwj0oMhMP5CV7r23tmlqYRxBsamlLoySwLaWuoMv0Svp7nH1P0aIPdq3w0pjisVYyVngjI6omJCNnU5J_DqmMJBp5OiRJ3TVFOaakpz9K_moYM5gPun5_hG8GYGOlvd-qSjDfnBMSo45bIa3dvJdcPxvzvnG0Pu4c8D1umnEjWvK9X8uFN0u919-nj3RTX8LwpbnFk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>224326121</pqid></control><display><type>article</type><title>Safety, Tolerability and Effectiveness of Generic HAART in HIV-Infected Children in South India</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Alma/SFX Local Collection</source><creator>Kumarasamy, N. ; Venkatesh, Kartik K. ; Devaleenol, Bella ; Poongulali, S. ; Mothi, S. N. ; Solomon, Suniti</creator><creatorcontrib>Kumarasamy, N. ; Venkatesh, Kartik K. ; Devaleenol, Bella ; Poongulali, S. ; Mothi, S. N. ; Solomon, Suniti</creatorcontrib><description>HIV-infected children in resource-limited settings are increasingly gaining greater access to highly active antiretroviral therapy (HAART) but documented longitudinal data remains limited. We aimed to study the clinical and immunological outcomes among 67 South Indian HIV-infected children with >18 months of follow-up on HAART at a tertiary HIV care program. The median CD4 cell count at enrolment was 290 cells μl−1 and at treatment initiation was 225 cells μl−1. Patients demonstrated a significant rise in their CD4 cell counts between treatment initiation and after 6 months (701 cells μl−1; p = 0.007), 12 months (741 cells μl−1; p = 0.037), and 18 months of therapy (718 cells μl−1; p = 0.005). The most common adverse events to therapy were nausea (20.9%) and rash (25.4%). Over one-fifth of patients (25.4%) substituted therapy due to toxicities and 19.4% of patients switched to second-line protease inhibitor-containing regimens. In this South Indian pediatric cohort, generic HAART was safe, effective and relatively well tolerated.</description><identifier>ISSN: 0142-6338</identifier><identifier>EISSN: 1465-3664</identifier><identifier>DOI: 10.1093/tropej/fmn080</identifier><identifier>PMID: 18829638</identifier><identifier>CODEN: JTRPAO</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Adolescent ; Anti-HIV Agents - adverse effects ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiretroviral Therapy, Highly Active - adverse effects ; Antiviral agents ; Biological and medical sciences ; CD4 Lymphocyte Count ; Child ; Child, Preschool ; Drugs, Generic - pharmacology ; Drugs, Generic - therapeutic use ; Female ; Follow-Up Studies ; General aspects ; HIV Infections - drug therapy ; HIV-1 - drug effects ; Human viral diseases ; Humans ; India - epidemiology ; Infant ; Infectious diseases ; Male ; Medical sciences ; Pharmacology. Drug treatments ; Treatment Outcome ; Viral diseases ; Viral diseases of the lymphoid tissue and the blood. Aids</subject><ispartof>Journal of tropical pediatrics (1980), 2009-06, Vol.55 (3), p.155-159</ispartof><rights>The Author [2008]. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org 2008</rights><rights>2009 INIST-CNRS</rights><rights>The Author [2008]. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c458t-22a2b177ca13d08e880b208feb0e014a5a7ffdc9b56bdbe0b288a5b90eacc1db3</citedby><cites>FETCH-LOGICAL-c458t-22a2b177ca13d08e880b208feb0e014a5a7ffdc9b56bdbe0b288a5b90eacc1db3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,1579,27905,27906</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21631385$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18829638$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kumarasamy, N.</creatorcontrib><creatorcontrib>Venkatesh, Kartik K.</creatorcontrib><creatorcontrib>Devaleenol, Bella</creatorcontrib><creatorcontrib>Poongulali, S.</creatorcontrib><creatorcontrib>Mothi, S. N.</creatorcontrib><creatorcontrib>Solomon, Suniti</creatorcontrib><title>Safety, Tolerability and Effectiveness of Generic HAART in HIV-Infected Children in South India</title><title>Journal of tropical pediatrics (1980)</title><addtitle>J Trop Pediatr</addtitle><description>HIV-infected children in resource-limited settings are increasingly gaining greater access to highly active antiretroviral therapy (HAART) but documented longitudinal data remains limited. We aimed to study the clinical and immunological outcomes among 67 South Indian HIV-infected children with >18 months of follow-up on HAART at a tertiary HIV care program. The median CD4 cell count at enrolment was 290 cells μl−1 and at treatment initiation was 225 cells μl−1. Patients demonstrated a significant rise in their CD4 cell counts between treatment initiation and after 6 months (701 cells μl−1; p = 0.007), 12 months (741 cells μl−1; p = 0.037), and 18 months of therapy (718 cells μl−1; p = 0.005). The most common adverse events to therapy were nausea (20.9%) and rash (25.4%). Over one-fifth of patients (25.4%) substituted therapy due to toxicities and 19.4% of patients switched to second-line protease inhibitor-containing regimens. In this South Indian pediatric cohort, generic HAART was safe, effective and relatively well tolerated.</description><subject>Adolescent</subject><subject>Anti-HIV Agents - adverse effects</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiretroviral Therapy, Highly Active - adverse effects</subject><subject>Antiviral agents</subject><subject>Biological and medical sciences</subject><subject>CD4 Lymphocyte Count</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Drugs, Generic - pharmacology</subject><subject>Drugs, Generic - therapeutic use</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>General aspects</subject><subject>HIV Infections - drug therapy</subject><subject>HIV-1 - drug effects</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>India - epidemiology</subject><subject>Infant</subject><subject>Infectious diseases</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Treatment Outcome</subject><subject>Viral diseases</subject><subject>Viral diseases of the lymphoid tissue and the blood. Aids</subject><issn>0142-6338</issn><issn>1465-3664</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqF0M-L1DAUB_AgijuuHr1KEAQP1s2PNs0ch2HdDq6Iziiyl5AfL2zGTjomrTj_vR1a1qOnF3gf3nv5IvSSkveULPlVn7oj7K_8IRJJHqEFLUVVcCHKx2hBaMkKwbm8QM9y3hNCmCzLp-iCSsmWgssFUlvtoT-9w7uuhaRNaEN_wjo6fO092D78hgg5487jm_GVgsXNavV1h0PEzeZ7sYlnBQ6v70PrEsRzY9sN_T3eRBf0c_TE6zbDi7leom8frnfrprj9fLNZr24LW1ayLxjTzNC6tppyRyRISQwj0oMhMP5CV7r23tmlqYRxBsamlLoySwLaWuoMv0Svp7nH1P0aIPdq3w0pjisVYyVngjI6omJCNnU5J_DqmMJBp5OiRJ3TVFOaakpz9K_moYM5gPun5_hG8GYGOlvd-qSjDfnBMSo45bIa3dvJdcPxvzvnG0Pu4c8D1umnEjWvK9X8uFN0u919-nj3RTX8LwpbnFk</recordid><startdate>20090601</startdate><enddate>20090601</enddate><creator>Kumarasamy, N.</creator><creator>Venkatesh, Kartik K.</creator><creator>Devaleenol, Bella</creator><creator>Poongulali, S.</creator><creator>Mothi, S. N.</creator><creator>Solomon, Suniti</creator><general>Oxford University Press</general><general>Oxford Publishing Limited (England)</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T5</scope><scope>7TM</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope></search><sort><creationdate>20090601</creationdate><title>Safety, Tolerability and Effectiveness of Generic HAART in HIV-Infected Children in South India</title><author>Kumarasamy, N. ; Venkatesh, Kartik K. ; Devaleenol, Bella ; Poongulali, S. ; Mothi, S. N. ; Solomon, Suniti</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c458t-22a2b177ca13d08e880b208feb0e014a5a7ffdc9b56bdbe0b288a5b90eacc1db3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adolescent</topic><topic>Anti-HIV Agents - adverse effects</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiretroviral Therapy, Highly Active - adverse effects</topic><topic>Antiviral agents</topic><topic>Biological and medical sciences</topic><topic>CD4 Lymphocyte Count</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Drugs, Generic - pharmacology</topic><topic>Drugs, Generic - therapeutic use</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>General aspects</topic><topic>HIV Infections - drug therapy</topic><topic>HIV-1 - drug effects</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>India - epidemiology</topic><topic>Infant</topic><topic>Infectious diseases</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Treatment Outcome</topic><topic>Viral diseases</topic><topic>Viral diseases of the lymphoid tissue and the blood. Aids</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kumarasamy, N.</creatorcontrib><creatorcontrib>Venkatesh, Kartik K.</creatorcontrib><creatorcontrib>Devaleenol, Bella</creatorcontrib><creatorcontrib>Poongulali, S.</creatorcontrib><creatorcontrib>Mothi, S. N.</creatorcontrib><creatorcontrib>Solomon, Suniti</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><jtitle>Journal of tropical pediatrics (1980)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kumarasamy, N.</au><au>Venkatesh, Kartik K.</au><au>Devaleenol, Bella</au><au>Poongulali, S.</au><au>Mothi, S. N.</au><au>Solomon, Suniti</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety, Tolerability and Effectiveness of Generic HAART in HIV-Infected Children in South India</atitle><jtitle>Journal of tropical pediatrics (1980)</jtitle><addtitle>J Trop Pediatr</addtitle><date>2009-06-01</date><risdate>2009</risdate><volume>55</volume><issue>3</issue><spage>155</spage><epage>159</epage><pages>155-159</pages><issn>0142-6338</issn><eissn>1465-3664</eissn><coden>JTRPAO</coden><abstract>HIV-infected children in resource-limited settings are increasingly gaining greater access to highly active antiretroviral therapy (HAART) but documented longitudinal data remains limited. We aimed to study the clinical and immunological outcomes among 67 South Indian HIV-infected children with >18 months of follow-up on HAART at a tertiary HIV care program. The median CD4 cell count at enrolment was 290 cells μl−1 and at treatment initiation was 225 cells μl−1. Patients demonstrated a significant rise in their CD4 cell counts between treatment initiation and after 6 months (701 cells μl−1; p = 0.007), 12 months (741 cells μl−1; p = 0.037), and 18 months of therapy (718 cells μl−1; p = 0.005). The most common adverse events to therapy were nausea (20.9%) and rash (25.4%). Over one-fifth of patients (25.4%) substituted therapy due to toxicities and 19.4% of patients switched to second-line protease inhibitor-containing regimens. In this South Indian pediatric cohort, generic HAART was safe, effective and relatively well tolerated.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>18829638</pmid><doi>10.1093/tropej/fmn080</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0142-6338 |
| ispartof | Journal of tropical pediatrics (1980), 2009-06, Vol.55 (3), p.155-159 |
| issn | 0142-6338 1465-3664 |
| language | eng |
| recordid | cdi_proquest_journals_224326121 |
| source | MEDLINE; Oxford University Press Journals All Titles (1996-Current); Alma/SFX Local Collection |
| subjects | Adolescent Anti-HIV Agents - adverse effects Antibiotics. Antiinfectious agents. Antiparasitic agents Antiretroviral Therapy, Highly Active - adverse effects Antiviral agents Biological and medical sciences CD4 Lymphocyte Count Child Child, Preschool Drugs, Generic - pharmacology Drugs, Generic - therapeutic use Female Follow-Up Studies General aspects HIV Infections - drug therapy HIV-1 - drug effects Human viral diseases Humans India - epidemiology Infant Infectious diseases Male Medical sciences Pharmacology. Drug treatments Treatment Outcome Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids |
| title | Safety, Tolerability and Effectiveness of Generic HAART in HIV-Infected Children in South India |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T02%3A32%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety,%20Tolerability%20and%20Effectiveness%20of%20Generic%20HAART%20in%20HIV-Infected%20Children%20in%20South%20India&rft.jtitle=Journal%20of%20tropical%20pediatrics%20(1980)&rft.au=Kumarasamy,%20N.&rft.date=2009-06-01&rft.volume=55&rft.issue=3&rft.spage=155&rft.epage=159&rft.pages=155-159&rft.issn=0142-6338&rft.eissn=1465-3664&rft.coden=JTRPAO&rft_id=info:doi/10.1093/tropej/fmn080&rft_dat=%3Cproquest_cross%3E1744954831%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=224326121&rft_id=info:pmid/18829638&rft_oup_id=10.1093/tropej/fmn080&rfr_iscdi=true |